Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Apr;14(4):816-819.
doi: 10.21037/jtd-22-98.

Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)

Giulio Metro  1 , Angelo Bonaiti  1 , Ilaria Birocchi  1 , Francesca Marasciulo  1 , Martina Ubaldi  1 , Niccolò Metelli  1 , Vincenzo Minotti  1 , Alfredo Addeo  2
Affiliations
Editorial

Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)

Giulio Metro et al. J Thorac Dis. 2022 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-98/coif). GM serves as an unpaid editorial board member of Journal of Thoracic Disease from February 2021 to January 2023. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-Cell lung cancer. N Engl J Med 2018;378:113-25. 10.1056/NEJMoa1713137 - DOI - PubMed
    1. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2020;382:41-50. 10.1056/NEJMoa1913662 - DOI - PubMed
    1. Mu Y, Hao X, Yang K, et al. Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib. Target Oncol 2019;14:335-42. 10.1007/s11523-019-00644-6 - DOI - PMC - PubMed
    1. Cortellini A, Leonetti A, Catino A, et al. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes. Clin Transl Oncol 2020;22:844-51. 10.1007/s12094-019-02193-w - DOI - PubMed
    1. Planchard D, Boyer MJ, Lee JS, et al. Postprogression outcomes for osimertinib versus standard-of-care EGFR-TKI in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer. Clin Cancer Res 2019;25:2058-63. 10.1158/1078-0432.CCR-18-3325 - DOI - PubMed